WASHINGTON — A patient advocate and a pharmaceutical industry representative went head to head Thursday on a proposal to peg U.S. drug prices to how much they cost in other countries — sparring over whether it is an idea whose time has come or the death knell for innovation.

Health secretary Alex Azar proposed last month a controversial change to the way Medicare pays for drugs administered in doctors’ offices that would tie some U.S. prices to the cost in other countries. The government would aim to pay about 30 percent less for certain drugs, with the price reduction for individual drugs related in some way to the average price of those drugs in certain other countries.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy